Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the marfan syndrome

Anji T. Yetman, Renee A. Bornemeier, Brian W. McCrindle

Research output: Contribution to journalArticle

137 Scopus citations

Abstract

Despite variable clinical results, β blockers have become the primary therapy for prevention of aortic dilation in patients with the Marfan syndrome. This study examines the use of the angiotensin-converting enzyme inhibitor enalapril for treatment of these patients. We sought to examine the effects of enalapril versus β-blocker therapy in patients with the Marfan syndrome and noted improved aortic distensibility (3.0 ± 0.3 vs 1.9 ± 0.4 cm2 dynes-1; p <0.02) and a reduced aortic stiffness index (8.0 ± 2.9 vs 18.4 ± 3.8; p <0.05) in patients receiving enalapril compared with those receiving β blockers. These favorable hemodynamic changes were associated with a smaller increase in aortic root diameter (0.1 ± 1.0 vs 5.8 ± 5.2 mm) and fewer clinical end points during follow-up.

Original languageEnglish (US)
Pages (from-to)1125-1127
Number of pages3
JournalAmerican Journal of Cardiology
Volume95
Issue number9
DOIs
StatePublished - May 1 2005

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the marfan syndrome'. Together they form a unique fingerprint.

  • Cite this